CytoDyn greenlit from Health Canada to file BLA for leronlimab as combination HIV therapy

2 Просмотры
Издатель
CytoDyn Inc. (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotech has been approved by Health Canada to file its Biologics License Application (BLA) for leronlimab as a combination HIV therapy for multi-drug resistance HIV patients in Canada.

What's more, Pourhassan says the group will change its flagship drug leronlimab's name to VYROLOGIX, and nine of the company’s trademark applications to register the mark have now successfully passed through formal examination. Final approval of Vyrologix as the name for leronlimab is conditional on FDA approval of the BLA and new drug application.
Категория
Здоровье
Комментариев нет.